MedTrace Logo

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

NCT03000179 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-04-14

Study results available
· View outcomes & findings →

Summary

This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.

Conditions

  • Adenocarcinoma

Interventions

DRUG

Avelumab

Avelumab through a vein once every 2 weeks

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • EMD Serono

    collaborator INDUSTRY

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Dana Cardin, M.D. · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2021-08-03
Completion
2021-08-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03000179 on ClinicalTrials.gov